Cas:916173-07-4 N-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]acetamide manufacturer & supplier

Chemical Name:N-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]acetamide

CAS.NO:916173-07-4

Synonyms:Acetamide,N-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]

Molecular Formula:C₁₅H₁₃N₃O

Molecular Weight:251.28300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:61.27000

Exact Mass:251.10600

LogP:3.83780

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Acetamide,N-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl] chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Acetamide,N-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl] physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Acetamide,N-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl] Use and application,Acetamide,N-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl] technical grade,usp/ep/jp grade.

Related News: A November 2020 analysis by researchers at the University of Oxford found Innova’s tests could be more or less accurate depending on who was using them—ranging from lab scientists to trained healthcare professionals to the general public—but determined the tests overall had a low failure rate and high specificity, despite some variations seen in production batches. Still, Innova’s test and antigen diagnostics more broadly have been seen as less accurate compared to gold-standard, lab-based PCR screening. N-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]acetamide manufacturer Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. N-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]acetamide supplier Refers to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs or innovative drugs). It mainly meets the needs of international original research drug companies and emerging biopharmaceutical companies for innovative drugs at various stages of clinical research, registration approval and commercialization of drugs. Contains advanced intermediates used in the manufacture of this drug substance that need to be regulated by regulatory authorities. N-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]acetamide vendor The new rules started Saturday — however if you’re an Australian citizen, permanent resident or their immediate family, or an aircrew member who has been using appropriate protective equipment, you’re exempt. N-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]acetamide factory It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion.